A certificate of analysis can be useful evidence, but only for the sample and tests it actually describes. Authenticating a certificate and deciding whether its results are sufficient are two different tasks.

First establish that the report is real

A laboratory or research team can check whether the document identifies the issuing laboratory, report number, sample, batch and test date. Where verification is available, it should use a contact or system independently established as belonging to that laboratory rather than an unverified link in a screenshot.

The next question is chain of custody. Who selected the sample, who submitted it and how does it relate to the delivered batch? A real report on a supplier-submitted sample is not automatically evidence of independent sampling across all saleable units.

Then examine what was measured

FDA's Q2 guidance explains why analytical procedures need to be appropriate for their intended purpose. Identity, assay, related substances and other quality attributes may require different procedures. A report should not be read as covering attributes it never tested. FDA Q2 R2 analytical procedure validation guidance

FDA's Q7 framework treats certificates as part of a broader quality system that includes specifications, supplier qualification and traceability. It does not reduce acceptance to possession of a PDF. FDA Q7 guidance for active pharmaceutical ingredient quality

A discrepancy between the product and report should be resolved before the material is used in a study. That may involve clarification, further qualified testing or rejection under the institution's procedure. It should not be fixed by assuming that similar-looking names refer to the same material.

AXON has not authenticated any vendor's certificate in this article. It offers a method for evaluating evidence without endorsing a company. Even a genuine, technically adequate research certificate does not establish FDA approval, clinical efficacy or suitability for human administration.